VivoSeq
Oncology

Solid Neoplasms

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Solid Neoplasms is an early-stage landscape with 1 program across 2 companies. The most active players are AstraZeneca, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Olaparib

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
Completed·National Cancer Institute (NCI)·Phase 1·NCT00117013·16 enrolled
Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms
Completed·TTheramab LLC·Phase 1·NCT03006029·12 enrolled
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT03742895·329 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)